Dolo-Maker Fights Back: Dilip Surana Debunks Paracetamol-Autism Link, Citing No Clear Evidence

In a powerful statement, Dilip Surana, the driving force behind the ubiquitous Dolo 650, has decisively rebutted recent claims by Robert F. Kennedy Jr. suggesting a link between paracetamol and autism. Surana asserted that there is no clear scientific evidence to establish such a connection, strongly advocating for the drug's continued safe and responsible use.

Surana's comments come amidst a growing concern over the spread of misinformation regarding common medications.

He emphasized that paracetamol, a widely trusted analgesic and antipyretic, has undergone rigorous scrutiny by global regulatory bodies. Both the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) have affirmed the safety profile of paracetamol, even for use during pregnancy, when taken according to prescribed dosages.

The Dolo 650 manufacturer highlighted that the consensus among leading medical and scientific organizations worldwide supports the safe use of paracetamol.

He cautioned against unsubstantiated claims that could lead to undue fear and discourage individuals, particularly parents, from using a crucial medicine for managing fever and pain.

Surana underscored the potential public health implications of such misinformation. Fevers, especially in children, can be dangerous if left unmanaged.

Paracetamol plays a vital role in controlling fever and alleviating discomfort, preventing more severe health complications. Disrupting its use based on unproven theories could inadvertently cause more harm than good.

By firmly standing on the side of evidence-based medicine, Dilip Surana aims to reassure the public and healthcare professionals about the continued safety and efficacy of paracetamol.

His message is a clear call for critical evaluation of health claims and a reliance on established scientific consensus from reputable medical authorities.